Analyst Price Targets — XNCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 1:15 pm | — | Truist Financial | $27.00 | $15.13 | TheFly | Xencor price target lowered to $27 from $29 at Truist |
| December 17, 2025 10:59 am | — | Barclays | $26.00 | $16.55 | TheFly | Xencor price target raised to $26 from $23 at Barclays |
| November 24, 2025 12:17 pm | — | Truist Financial | $29.00 | $15.87 | TheFly | Xencor initiated with a Buy at Truist |
| November 6, 2025 1:57 pm | — | Cantor Fitzgerald | $42.00 | $14.75 | TheFly | Xencor price target raised to $42 from $40 at Cantor Fitzgerald |
| October 29, 2025 8:37 am | Etzer Darout | Barclays | $23.00 | $14.25 | TheFly | Xencor upgraded to Overweight from Underweight at Barclays |
| October 27, 2025 12:43 pm | Gregory Renza | RBC Capital | $18.00 | $13.83 | TheFly | Xencor price target raised to $18 from $15 at RBC Capital |
| September 16, 2025 8:49 pm | — | Barclays | $6.00 | $8.62 | TheFly | Xencor assumed with an Underweight at Barclays |
| August 7, 2025 1:03 pm | David Nierengarten | Wedbush | $26.00 | $7.32 | TheFly | Xencor price target lowered to $26 from $31 at Wedbush |
| February 28, 2025 1:37 pm | — | Wedbush | $31.00 | $15.36 | TheFly | Xencor price target lowered to $31 from $38 at Wedbush |
| December 2, 2024 8:43 am | Edward Tenthoff | Piper Sandler | $30.00 | $25.60 | StreetInsider | Piper Sandler Upgrades Xencor, Inc. (XNCR) to Overweight |
Latest News for XNCR
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal cell carcinoma (ccRCC) were accepted for a proffered paper oral presentation at the…
Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR's oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR's valuation in the near…
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XNCR.
U.S. House Trading
No House trades found for XNCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.